Stockscreener 앱 받기
66.04
0.69%
0.45
시간 외 거래:
67.34
1.30
+1.97%
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance
Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating - MarketScreener
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - Investing News Network
Kymera Therapeutics Begins Dosing Patients in Phase 2 Trial of Potential Dermatitis Treatment - MarketScreener
Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis - Investing.com Australia
Kymera initiates phase 2b trial of oral STAT6 degrader for atopic dermatitis By Investing.com - Investing.com South Africa
Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader - GlobeNewswire Inc.
Kymera Therapeutics stock hits 52-week high at 68.65 USD By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at 68.65 USD - Investing.com India
Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times
SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan
Neo Ivy Capital Management Purchases 6,079 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat
Will Kymera Therapeutics Inc. stock benefit from infrastructure spendingWeekly Trading Summary & Safe Entry Momentum Stock Tips - newser.com
Kymera at Jefferies Conference: Targeted Protein Degradation Focus - Investing.com India
Kymera at Jefferies Conference: Targeted Protein Degradation Focus By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Kymera Therapeutics Inc. meeting your algorithmic filter criteriaJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week HighStill a Buy? - MarketBeat
Behavioral Patterns of KYMR and Institutional Flows - news.stocktradersdaily.com
Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat
How analysts rate Kymera Therapeutics Inc. stock todayJuly 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Stifel reiterates Buy rating on Kymera Therapeutics stock ahead of December data - Investing.com Canada
Is Kymera Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Why Kymera Therapeutics Inc. stock could outperform in 2025Trade Risk Summary & Weekly Top Performers Watchlists - Fundação Cultural do Pará
How to read the order book for Kymera Therapeutics Inc.Bear Alert & Low Risk High Reward Trade Ideas - newser.com
Kymera at TD Cowen Summit: Strategic Moves in Immunology By Investing.com - Investing.com Canada
What analysts say about Kymera Therapeutics Inc stockMoving Average Crossovers & Subscribe for Free Weekly Winners - earlytimes.in
What valuation multiples suggest for Kymera Therapeutics Inc. stock2025 Year in Review & Reliable Volume Spike Trade Alerts - newser.com
What drives Kymera Therapeutics Inc stock priceStock Liquidity Analysis & Free Rapid Growing Investment Returns - earlytimes.in
Kymera Therapeutics stock hits 52-week high at 64.0 USD By Investing.com - Investing.com Philippines
Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout - MSN
Kymera at Stifel Conference: Strategic Insights on Drug Development By Investing.com - Investing.com UK
Kymera Therapeutics stock hits 52-week high at 64.0 USD - Investing.com
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Pattern recognition hints at Kymera Therapeutics Inc. upsideAnalyst Downgrade & Reliable Price Action Trade Plans - newser.com
Transcript : Kymera Therapeutics, Inc. Presents at UBS Global Healthcare Conference 2025, Nov-10-2025 11 - MarketScreener
What is HC Wainwright's Forecast for KYMR FY2025 Earnings? - MarketBeat
Equities Analysts Set Expectations for KYMR FY2025 Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen - MarketBeat
Kymera Therapeutics (KYMR) Gets a Buy from RBC Capital - The Globe and Mail
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges - MSN
Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Kymera Therapeutics Reports Q3 2025 Financial Results - MSN
Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail
HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN
Kymera upped to overweight by Wells Fargo on upcoming data - MSN
0.53%
1.88%
자본화:
|
볼륨(24시간):